Reduced tumor volume and melanoma bone metastasis via activation of ERK 1/2 and Akt pathways in vitro. Vactosertib is in phase I to treat solid tumors and in phase II for the treatment of non-small cell lung cancer. The gene discussed is AKT1; the disease is melanoma.